Navigation Links
Ferndale and Foamix Enter Development of an Innovative Foam for the Treatment of Atopic Dermatitis
Date:11/5/2007

FERNDALE, Michigan and NESS ZIONA, Israel, November 5 /PRNewswire/ -- Ferndale Laboratories Inc. and Foamix Ltd. announced today that the two companies have agreed to jointly develop non-steroidal foam for the treatment of atopic dermatitis.

According to this agreement, Foamix will be responsible for developing the foam formulations and Ferndale will have an option to continue definitive development and worldwide commercialization of the product. Additional terms were not disclosed.

Atopic dermatitis is very common in all parts of the world. It affects about 10% of infants and 3% of the total population in the United States. It can occur at any age but is most common in infants to young adults. The skin rash is very itchy and can be widespread, or limited to a few areas.

The development of the foam product will be directed to fortify the skin barrier by delivering a very high concentration of barrier-enhancing oils in an easy-to-apply formulation. Non-steroidal therapy is important for safe, long-term management of atopic dermatitis and the associated symptoms. Poor adherence to maintenance treatment for atopic dermatitis and parental anxiety about using topical steroids are common features seen among children with atopic dermatitis, and therefore, foams, which do not need extensive rubbing for spreading and absorption, offer an improved treatment modality for this disease.

"We believe that the Foamix foam offers an effective and convenient way to deliver treatment to patients with atopic dermatitis. These are often very young children who would benefit from the ease and comfort of use, combined with the efficacy of treatment," said James T. McMillan II, Chief Executive Officer of Ferndale.

"We are very proud to partner with an industry leader such as Ferndale," said Foamix CEO Dr. Dov Tamarkin. "Foam offers properties that increase usability, encourage compliance and boost user satisfaction. Foamix foams are alcohol-free and they can be designed to provide skin barrier properties, which are crucial for effective atopic dermatitis treatment, while using delicate, FDA approved ingredients, to ensure the safety of the patients," he noted.

About Ferndale

Ferndale is a specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription pharmaceutical products in the under-served medical specialties of dermatology, colon/rectal surgery and OB-Gyn.

Read more on http://www.ferndalelabs.com.

About Foamix:

Headquartered in Ness Ziona, Israel, Foamix Ltd. is a specialty pharmaceutical company focused on the development of topical foam products for prescription, OTC and cosmetic applications. Foamix's state-of-the-art foams provide controlled delivery of a variety of active ingredients. Foamix is a privately held company, whose business model is based on partnering with leading pharma companies to develop products utilizing its proprietary foam technologies. We currently collaborate with 8 pharmaceutical companies on 10 projects in the development of proprietary dermatological and gynecologic foam drugs; and we have our own in-house pipeline of dermatological and gynecological drugs in foam presentation.

The company's development capabilities range from initial development of foam formulations to scale-up, GMP manufacturing, preclinical and clinical studies. Foamix holds 3 US patents and has 48 US patents pending, with corresponding national applications worldwide.

For additional information please visit http://www.foamix.co.il

Press inquiries: Sigal Maymon, Foamix Ltd, +972-8-9316233 or info@foamix.co.il


'/>"/>
SOURCE Foamix Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
2. Cepheid Enters Into Five-Year Agreement With Northrop Grumman for the Purchase of Anthrax Test Cartridges for Use in United States Postal Service Biohazard Detection Systems
3. Baxa Announces 2008 Dates for STAR Center Professional Pharmacy and Cleanroom Training
4. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
5. Vital Images Releases Next Generation Enterprise-Wide Solutions Featuring Vitrea(R) 4.0 and ViTALConnect(R) 4.1
6. UniCare Unveils Community Resource Center in Topeka to Serve Medicaid Enrollees
7. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
8. Neogen Acquires Kane Enterprises
9. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
10. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
11. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... April 29, 2016 Elekta is ... update to its industry-leading treatment planning software, is available ... Monaco version 5.11 provides significant performance ... calculation speeds up to four times faster than in ... the industry,s gold standard Monte Carlo ...
(Date:4/28/2016)... ... April 28, 2016 , ... Next week on May ... its first-in-class technologies for tissue stem cell counting and expansion to gene-editing scientists ... Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. , The attention of most ...
(Date:4/27/2016)... ... April 27, 2016 , ... Shimadzu ... at the Spring 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments enable ... metals, and more. Expo attendees can stop by booth 1021 to learn how ...
(Date:4/27/2016)... SILVER SPRING, Md. and RESEARCH ... -- United Therapeutics Corporation (NASDAQ: UTHR ) announced ... Co-Chief Executive Officer, of United Therapeutics will provide an ... Deutsche Bank 41 st Annual Health Care Conference. ... May 5, 2016, at 10:00 a.m. Eastern Time, and ...
Breaking Biology Technology:
(Date:4/14/2016)... 2016 BioCatch ™, the ... announced the appointment of Eyal Goldwerger as ... Goldwerger,s leadership appointment comes at a time of ... deployment of its platform at several of the world,s ... discerns unique cognitive and physiological factors, is a winner ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
(Date:3/17/2016)... ABI Research, the leader in transformative ... market will reach more than $30 billion by ... Consumer electronics, particularly smartphones, continue to boost the ... reach two billion shipments by 2021 at a ... Research Analyst at ABI Research. "Surveillance is also ...
Breaking Biology News(10 mins):